阿伐卡西单抗 Pegol：首次批准。
Avacincaptad Pegol: First Approval.
机构信息
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
出版信息
Drugs. 2023 Oct;83(15):1447-1453. doi: 10.1007/s40265-023-01948-8.
Avacincaptad pegol (IZERVAY™; formerly Zimura) is a complement C5 inhibitor that is being developed by IVERIC Bio, an Astellas company, for the treatment of geographic atrophy secondary to age-related macular degeneration. Avacincaptad pegol recently received approval for the treatment of adults with geographic atrophy secondary to age-related macular degeneration. This article summarizes the milestones in the development of avacincaptad pegol leading to this first approval for geographic atrophy secondary to age-related macular degeneration.
依维莫司结合物（IZERVAY™；前称 Zimura）是一种补体 C5 抑制剂，由安斯泰来公司旗下的艾力维生物公司开发，用于治疗与年龄相关的黄斑变性相关的地图状萎缩。依维莫司结合物最近获得批准，用于治疗与年龄相关的黄斑变性相关的地图状萎缩的成年患者。本文总结了依维莫司结合物的开发历程中的重要里程碑，这些里程碑最终促成了其首次获批用于治疗与年龄相关的黄斑变性相关的地图状萎缩。
Zotero 插件